Episode Description
What will it take for in vivo CAR-T to move from oncology success to autoimmune breakthrough? Our latest episode breaks down what’s next, covering delivery choices, global trial design, and the evidence payers are looking for, so you can make sharper, faster decisions without the noise.
Join Pete Robinson, Therapeutic Strategy Director, Novotech for this discussion on:
- Which delivery paths (and their trade‑offs) matter now—and how they shape first‑in‑human design.
- Why Phase 1 siting is shifting and what it means for speed, budget, and data credibility.
- The single metric everyone will watch to judge success—and how it ties to dosing strategy.
- When to start commercialization planning (earlier than you think) and what to line up for payers and patients.